## **Trustees’ Annual Report for the period**
**From 1[st] January 2024 To 31[st] December 2024**
## **Charity name: Salivary Gland Cancer UK**
## **Charity registration number: 1182762**
## **Objectives and Activities**
||SORP reference||
|---|---|---|
|Summary of the purposes of
the charity as set out in its
governing document|Para 1.17|Help those affected by rare salivary gland
cancers.
Advocate for these patients and carers by
providing peer support and information
about their disease, care and treatment.
Promote and assist research into all aspects
of salivary gland cancers, including causes,
diagnosis, treatments and cures.
To educate the public and healthcare
communities in all things related to salivary
gland cancers, including raising awareness
of symptoms.|
|Summary of the main
activities in relation to those
purposes for the public
benefit, in particular, the
activities, projects or
services identified in the
accounts.|Para 1.17 and
1.19|•
Supporting the community via in person
and virtual meetings for patients, carers
and clinicians.
•
Providing information and increasing
awareness via leaflets, meetings, the
website, social media and fundraising
events.
•
Raising awareness of these cancers and
their
unmet
need
via
speaking,
submitting
materials
and
attending
meetings and conferences.
•
Expansion of the network to support all
salivary gland cancer types.
•
Expansion of the charity’s outputs to
provide more research and disease
specific information.|
|Statement confirming
whether the trustees have
had regard to the guidance
issued by the Charity
Commission on public
benefit|Para 1.18|The trustees have kept in mind the charity
Constitution and the guidance from the
Charities Commission in all of its’ activities.
The governance documents of the Charity
are regularly reviewed at Trustee meetings.
The charity’s “8 aims” are regularly
published via our social media outlets and
are the foundation for all activities and|
decisions within the charity. The trustees ensure the prioritisation of activities is aligned with these aims.
**Additional information (optional)** You may choose to include further statements where relevant about:
||SORP reference||
|---|---|---|
|Policy on grant making|Para 1.38|Following our first call for grant applications
in August 2023, we subsequently awarded
£36,600 to two projects. Both projects are
now underway and £21,000 was paid out
across of these initiatives in 2024. The
Board receives regular progress updates
regarding these grants.|
|Policy on social investment
including program related
investment|Para 1.38||
|Contribution made by
volunteers|Para 1.38|We are hugely grateful for the support and
contribution we received from our
volunteers assisting us in specific projects
and outputs, sharing their stories on social
media channels, and ‘on the day’ physical
support at our events.|
|Other|||
## **Achievements and Performance**
||SORP reference||
|---|---|---|
|Summary of the main
achievements of the charity,
identifying the difference the
charity’s work has made to
the circumstances of its
beneficiaries and any wider
benefits to society as a
whole.|Para 1.20|•
**_Bringing together those living with_**
**_salivary gland cancers_**
We continued to host bi-annual hybrid (in
person/virtual)
meetings
during
2024,
supporting attendees with travel bursaries
for patients and their carers where needed.
The hybrid structure of our events has
facilitated strong attendance from our
community
across
the
country
and
internationally. In March 2024 we hosted a
gathering in Manchester and October
2024’s event was in London.
We
provided
regular
communications,
newsletters and webinars to the network.
We continued to produce our video series,
releasing recordings of the presentations at
our hybrid meetings to ensure we reach as
many
people
as
possible.
We
also
continued to add patient stories on social
media and on our website.|
|2024 marked our 5 year anniversary and the|
|---|
|publishing of our 5 year impact report, “The|
|Story So Far.” The report focused on how|
|the collaboration between patients and|
|clinicians has been very impactful since the|
|charity’s inception and highlights what has|
|been achieved over this period.|
|•
**_Raising_**
**_awareness_**
**_amongst_**
**_the_**|
|**_general_**
**_public_**
**_and_**
**_the_**
**_clinical_**|
|**_community_**|
|We continue to work to increase our visibility|
|among the clinical and patient network by|
|attending
and
presenting
at
various|
|conferences and events.|
|In February we presented at the CRUK CNS|
|forum and at the 2ndAnnual Clinical|
|Outsourcing
Group
conference.
We|
|attended the LifeArc Translational Science|
|Summit in April where we engaged in|
|various discussions on how translational|
|science can potentially bridge the gap|
|between
basic
research
and
clinical|
|applications.
The
event
featured|
|presentations and valuable insights from|
|leading scientists, experts, policy makers|
|and innovators.|
|In May we visited Westminster and attended|
|the Cancer52 launch of their manifesto to|
|transform outcomes for people with rare|
|cancers. We hosted a stall and spoke at the|
|Oncology
and
Professional
Care|
|Conference. In September we attended the|
|ESMO Congress in Barcelona and in|
|November we hosted a stall and presented|
|at the Swallows International Head and|
|Neck Cancer Conference.|
|During the year, SGC UK joined the|
|PRONTO Study Management Group, who|
|are investigating the role of proton beam|
|therapy for patients needing adjuvant|
|radiotherapy. We also became members of|
|the Northern Head and Neck Alliance.|
|Our Patient and Public Involvement (PPI)|
|work has continued to grow and develop in|
|2024. We are regularly called upon to input|
|into the design of research studies, provide|
|feedback on trial protocols, help researchers|
|develop lay summaries of their work and|
|bring the perspective of those with lived|
|experiences to discussions.|
|Many fund raising events, both large and|
|small, have taken place during the year,|
|notably our supporters’ participation in the|
|---|
|Brighton and London Marathons.|
|•
**_Bringing together the patient, clinical_**|
|**_and research communities to help_**|
|**_drive_**
**_forward_**
**_research_**
**_and_**|
|**_improvements in treatments_**|
|Following the closure of the National Cancer|
|Research Institute (NCRI) and SGC UK|
|taking forward the research activities in|
|relation to salivary gland cancer, the|
|Research Working Group has been very|
|active during 2024.|
|Our inaugural meeting in March 2024 was|
|attended by clinicians, researchers and|
|patient advocates from all around the UK|
|and beyond. Knowledge and expertise were|
|shared, and four key areas of research were|
|identified. Workstreams are now in place to|
|address these areas which also align with|
|the charity’s aims.|
**Additional information (optional)** You may choose to include further statements where relevant about:
Achievements against Para 1.41 objectives set Performance of fundraising Para 1.41 activities against objectives set Investment performance Para 1.41 against objectives Other
## **Financial Review**
|Review of the charity’s
financial position at the end
of the period|Para 1.21|As at 31stDecember 2024 the charity held a
cash balance of £68,381, (prior year
£104,832). The charity had an in-year deficit
of £36,451 (prior year surplus £56,736).
The charity received income of £37,336 (prior
year £90,250) from donations raised through
fund raising initiatives and personal legacies.
The charity’s accounts for the year have been
independently reviewed with no issues
raised. TBC
Despite an in-year deficit, the charity’s
financial position remains robust. There was
a material increase in donations in 2023,
allowing sufficient brought forward funds to
support the initiatives in 2024, including the
issuance of two grants.|
|---|---|---|
|Statement explaining the
policy for holding reserves
stating why they are held|Para 1.22|The cash balance is held in order to support
the overall objectives of the charity. Cash is
used to cover operating expenses, develop
the charity’s presence through marketing and
fund specific patient/clinician events. Cash
held is also the source funds for the grants we
have issued and for any other grant making
opportunities that may arise.|
|Amount of reserves held|Para 1.22|£68,381 in cash.|
|Reasons for holding zero
reserves|Para 1.22|Not applicable|
|Details of fund materially in
deficit|Para 1.24|Not applicable|
|Explanation of any
uncertainties about the
charity continuing as a going
concern|Para 1.23|There are no uncertainties around the
charity’s ability to continue as a going
concern. The Board carefully consider the on-
going running costs of the charity when
assessing the funds available for grants and
other events.|
## **Additional information (optional)** You may choose to include further statements where relevant about:
|The charity’s principal
sources of funds (including
any fundraising)|Para 1.47||
|---|---|---|
|Investment policy and
objectives including any
social investment policy
adopted|Para 1.46||
|A description of the principal
risks facing the charity|Para 1.46|The Board maintains a Risk Register for
the charity. This document highlights
governance, operational, financial,
compliance and external risks and the|
mitigants in place. The Board reviews the Risk Register periodically. Other
## **Structure, Governance and Management**
|Description of charity’s
trusts:|||
|---|---|---|
|Type of governing document
(trust deed, royal charter)|Para 1.25|The charity is governed by its Constitution.|
|How is the charity
constituted?
(e.g unincorporated
association, CIO)|Para 1.25|The charity is a Charitable Incorporated
Organisation.|
|Trustee selection methods
including details of any
constitutional provisions e.g.
election to post or name of
any person or body entitled
to appoint one or more
trustees|Para 1.25|Trustees must be appointed for a term of
three years by a resolution passed at a
properly convened meeting of the charity
trustees.
When selecting trustees, the charity trustees
have regard to the skills, knowledge and
experience
needed
for
the
effective
administration of the CIO. The Board
periodically reviews a detailed skills matrix
to identify any gaps and regularly discusses
the structure and composition of the Board
to ensure its ongoing effectiveness as a
governing body.|
**Additional information (optional)** You may choose to include further statements where relevant about:
Policies and procedures Para 1.51 adopted for the induction and training of trustees The charity’s organisational Para 1.51 structure and any wider network with which the charity works Relationship with any related Para 1.51 parties Other
## **Reference and Administrative details**
|Charity name|Salivary Gland Cancer UK|
|---|---|
|Other name the charity uses||
|Registered charity number|1182762|
|Charity’s principal address|International House
36-38 Cornhill
City of London
London
EC3V 3NG|
|||
## **Names of the charity trustees who manage the charity**
|1
2
3
4
6
7
8
9
10
11
12
13
14
15|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**
**year **|**Name of person (or body) entitled**
**to appoint trustee (ifany)**|
|---|---|---|---|---|
||Emma Jane
Kinloch|Trustee and Chair||The Board|
||Dr Robert Metcalf|Trustee||The Board|
||Shane Lisa Draper|Trustee and Chief
Financial Officer||The Board|
||Olorunkemi Fausat
Akanke Olaiya|Treasurer|**Non-Board role|The Board|
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
## – Corporate trustees names of the directors at the date the report was approved
## **Director name**
Name of trustees holding title to property belonging to the charity
**Trustee name Dates acted if not for whole year**
## **Funds held as custodian trustees on behalf of others**
Description of the assets Not applicable held in this capacity Name and objects of the Not applicable charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for Not applicable safe custody and segregation of such assets from the charity’s own assets
## **Additional information (optional)**
## **Names and addresses of advisers (Optional information)**
|**Type of**|**Name**|**Address**|
|---|---|---|
|**adviser**|||
**Name of chief executive or names of senior staff members (Optional information)**
## **Exemptions from disclosure**
Reason for non-disclosure of key personnel details
## **Other optional information**
Declarations
The Iruslaes declare that they havo approved the trustees. report abov•.
Slgned on behalf of the charity's trustees
Slgnaturels
Full namelsl
Posltlon (og Secretary,
Chalr. etc)
Emma Jane Kin1(
Shane Lisa Draper
Chair
Chief Financial Officer
Dats
OLS
CHARITY COMMISSION
Foq ENGLAND AND WAIES
Recei
tsand
ments accounts
CC16a
To
l•iJ•r
2014
31xt tl•c•rnb•w 2•24
Section A Recei
ts and
ments
un$1¢2ed
Totsltunds
AI RK•l l•
p<r
SubloL•llGmss income TAR)
J?.x
.210
A? A*¥•i •nd Inv•#m•*t ••l*.
S1•1
37.jm
J?.J
10,260
i•
JJ.io•
In • q
17.J7•
17.Y•
1J,7¥0
ln
trrtry tréDrrt# Ir* mwrkn
1.$10
1.$1•
717
73.7•7
,014
A• AM•1 •nd Inv•Atm•nl
73,717
7J.717
33.514
14•iof rec•lptsip•ym•nts)
AS Tmnth b•tw••n lund•
A6 Ctth funds l•Bt y•w•nd
C•8h luftdt 114s y•*r•nd
J6.451
,736
104.•32
104.J32
60.J81
48.098
104.832
Section B Statement of assets and liabilities at the end of the
eriod
fund•
B1 Calh fw
Toi•lush fw**s
fund•
fund
B2 Other mon•tary u••ts
03 In¥ts•I ••••l•
B4 A•••ts r•tslMdfvr th•
¢hrlty'# uA•
s1on•O byon• knJ•t•••C47
##
##
##
##